Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

July 1, 2025

Study Completion Date

March 1, 2027

Conditions

Carcinoma, Non-Small-Cell LungBrain MetastasesLeptomeningeal Metastasis

Interventions

DRUG

Lorlatinib

Lorlatinib 100 mg once daily on days 1 to 28 of each 28-day cycle

Trial Locations (1)

Guangdong Provincial Perople's Hospital, Guangzhou

All Listed Sponsors

lead

Guangdong Association of Clinical Trials

OTHER

NCT06282874 - Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases | Biotech Hunter | Biotech Hunter